FDA Updates SOPP 8001.4 on Proprietary Name Review for Biologics

The U.S. Food and Drug Administration (FDA), through its Center for Biologics Evaluation and Research (CBER), has released Version 9 of SOPP 8001.4, effective April 10, 2026, outlining the review process for proprietary (brand) names of biologic products.

What’s new?

The latest revision introduces minor editorial updates and corrections, with no substantive policy changes compared to Version 8.

Key regulatory principles (unchanged but reinforced)

1. Focus on patient safety and medication error prevention

FDA continues to emphasize that name similarity (look-alike/sound-alike) is a major contributor to medication errors—accounting for up to 25% of cases.

Evaluation includes:

• Phonetic and orthographic analysis (via POCA system)

• Screening for misleading or promotional claims

• Risks from naming conventions (e.g., umbrella branding, modifiers, reuse of names)

2. Clear acceptability categories

Proprietary names are classified as:

• Acceptable

• Acceptable at this time (early-stage/IND)

• Unacceptable (requires resubmission)

3. Strict submission and review timelines

• IND stage: 180 days

• BLA/NDA/ANDA stage: 90 days

• For rolling submissions, review starts only after the final module is received

4. Limited flexibility for applicants

• Maximum of two proposed names per submission

• No reservation of names

• Names cannot be reused or transferred across products

• Acceptance is product-specific (no cross-product applicability)

5. Formal challenge pathway

If a name is rejected:

• Sponsors may submit a rebuttal or

• Request a Type C meeting within 60 days

Why this matters for manufacturers

Although this SOPP does not apply to medical devices or IVDs under MDR/IVDR, it highlights regulatory expectations that are increasingly relevant across sectors:

Branding strategy must be risk-based

Even outside FDA biologics, regulators globally (including EU MDR) are increasingly sensitive to:

• Misleading product claims

• Confusion risks in labeling and IFU

• Consistency across product families

Early planning is critical

The structured timelines and limited resubmission flexibility reinforce the need to:

• Validate naming early in development

• Align branding with regulatory and clinical positioning

Cross-functional alignment is essential

Naming is not just marketing:

• It intersects with risk management (ISO 14971)

• Labeling and usability (e.g., IEC 62366-1)

• Post-market surveillance (error trends)

Read the full document below.